BP Lipid 222 BP Lipid 222 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315 (BP-25498). The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

BP Lipid 211 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. Both ester bonds are located at C10 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery.

BP Lipid 309 is an ionizable lipid analogue of ALC-0315 featuring a tertiary amine head, a central tertiary amine, and two identical esters linking to nonpolar tails. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 307 is a multi-ionizable amino-lipid featuring a dimethylamine headgroup, a central tertiary amine, and two identical ester branches linking to saturated C17 tails. This compound may be employed in the development of lipid nanoparticles for drug delivery.

BP Lipid 318 is a lipid analog comprised of three unsaturated fatty acid tails and an ionizable dimethylamino butanoate head group. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.

BP Lipid 316 is an ionizable lipid analogue of DLin-MC3-DMA featuring a 4-(dimethylamino)butanoate head, two linoleic acid tails, and one primary alcohol. The alcohol may be used to further derivatize this compound. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 317 is an amino lipid featuring a dimethylamine headgroup connected to two oleic esters and a hydroxy group which may be used for further derivatization. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 320 is an ionizable amino lipid comprised of three oleic fatty acid tails and a novel pyrrolidine head group four carbon atoms in length. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.

BP Lipid 315 is a cationic ionizable lipid ALC-0315 analogue featuring a Boc-protected primary amine, a central tertiary amine, and two ester tails located at the C8 position relative to the amine. One of these esters features a symmetrical branched C17 tail, while the other is an asymmetric C11 tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 319 is a multi-ionizable amino lipid analogue of ALC-0315 featuring a propylamino headgroup and two acyl tails, one being a branched symmetrical C17 and the other being an asymmnetrical C11 chain. Ionizable lipids such as this may be applied in the development of lipid nanoparticles.

BP Lipid 312 is a cationic ionizable lipid analogue of LP01, with the substitution of a polyunsaturated tail for a monounsaturated equivalent. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 311 is a branched amino lipid featuring a dimethylamino headgroup, esters of a palmitoleic acid group and an aliphatic acetal. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 308 has a terminal tertiary amine group, a linoleic group, and a 4,4-bis(octyloxy)butanoic acid sodium salt tail. This compound can be useful for the building or modification of lipid nanoparticles. Reagent grade, for research use only.

BP Lipid 314 is an ionizable amino lipid featuring a dimethylamino head group, a carbamate linking to a central tertiary carbon with two other branches, a linoleate ester, and an aliphatic acetal ester. A compound like this may be employed in the development of lipid nanoparticles for drug delivery.

BP Lipid 310 is an ionizable aminolipid analog of CL1. The structure features an ethanolamine head and an ester linking to a polyunsaturated hydrophobic tail. This lipid may be used to encapsulate nucleic acids or small-molecule drugs to form lipid nanoparticles for drug discovery.

BP Lipid 323 is an ionizable aminolipid analog of CL1 which features a unique azetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 321 is an ionizable aminolipid analog of CL1 which features a unique 3-hydroxyazetidine head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

BP Lipid 322 is a multichargeable lipid analog of CL1 which features a novel 2-hydroxyethyl piperazine ionizable head and an ester linking to a polyunsaturated hydrophobic tail. Ionizable lipids such as this may be applied in the development of lipid nanoparticles for drug discovery.

Al-28 is a multi-ionizable aminolipid featuring a central amine and three identical disulfide-linked saturated side chains. The hydrophobic side chains are linked to the central structure by ester as well as disulfide bonds. Disulfide bonds are readily cleaved in the reducing environment of the cell cytoplasm. Ionizable lipids are typically used in the design of nucleic acid lipid nanoparticles, as their pH-dependent positive charge stabilizes the anionic nucleic acids they encapsulate.

9A1P9 is a multi-tail ionizable cationic phospholipid. 9A1P9 induces membrane destabilization. 9A1P9 can be used for CRISPR-Cas9 gene editing in mice.

ALC-0315 analogue-1 (compound P-10) is a cationic lipid. ALC-0315 analogue-1 is the raw material for synthesis of cationic liposome.

BLU-451, also known as LNG-451, orally bioavailable, central nervous system (CNS) penetrating, mutant-selective covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) activating mutations, with potential antineoplastic activity. Upon oral administration, EGFR Ex20ins inhibitor BLU-451 selectively targets, irreversibly binds to and inhibits the activity of EGFR Ex20ins and some other oncogenic point mutations. This prevents EGFR Ex20ins-mediated signaling. This may induce cell death and inhibit tumor growth in EGFR Ex20ins-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumors, plays a key role in tumor cell proliferation and tumor vascularization. BLU-451 is able to penetrate the blood-brain-barrier (BBB) and may therefore exert its activity against EGFR Ex20ins-driven CNS primary tumors and CNS metastases. BLU-451 does not inhibit the activity of wild-type (WT) EGFR. EGFR Ex20ins are oncogenic driver mutations that constitutively upregulate kinase activity.

VK-2019 is a selective EBNA1 inhibitor. VK-2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV-associated carcinomas. EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells.

PDE4B-IN-2 is an orally active and selective PDE4B inhibitor with an IC50 of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC50=1.7 µM). PDE4B-IN-2 exhibits potent anti-inflammatory effects.

PRMT5 inhibitors; PRMT5 inhibitors;

NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.

UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2.

AK59-51TB (AK59) is a STING degrader leveraging HERC4, a HECT-domain E3 ligase.

IDE397 is a potent inhibitor of MAT2A, which is developed to selectively exploit this synthetic lethal vulnerability in MTAP−/− tumors.

Compound 32 (HER2) is a potent and selective covalent inhibitor of HER2/WT and HER2/YVMA with IC50 of 49 nM and 42 nM, respectively.

IDOR-1117-2520 is a selective and insurmountable antagonist of CCR6 with IC50 of 20 nM.

Pidobenzone is a dermatologic agent.

Pseudouridine-5’-triphosphate (Pseudo-UTP) is one of the most commonly used modified nucleoside for the polymerase-mediated synthesis of RNA molecules. Compared with uridine-containing unmodified mRNAs, the application of pseudouridine-containing modified mRNAs exhibits better nuclease stability, immunogenicity, and translational properties.

LSN3441732 is a dimeric compound and inhibits the formation of Lipoprotein(a) (Lp(a)) particles in vitro with IC50 of 0.18 nM.

R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.

BIO-8169 is a highly potent, selective, and brain-penetrant IRAK4 inhibitor with IC50 of 0.2 nM. BIO-8169 has an excellent PK profile, reduces the in vivo production of pro-inflammatory cytokines, and is tolerated in toxicity studies in rodents and dogs.

Nelutroctiv (CK-136) is a novel cardiac troponin activator devoid of PDE-3 activity that demonstrates a wider pharmacodynamic window in vivo relative to a representative myosin activator, CK-138.

TAC is a TERT activator compound that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. TAC alleviates neuroinflammation, increases neurotrophic factors, stimulates adult neurogenesis, and preserves cognitive function without evident toxicity, including cancer risk.

GalNAc-L96-tert-butyl ester is a cleavable PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane is also a PEG/Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.

dWIZ-1 is a molecular glue degrader of the WIZ transcription factor that robustly induce HbF in erythroblasts. dWIZ-1 increases CRBNWIZ association with EC50 of 547 nM.

dWIZ-2 is a molecular glue degrader of the WIZ transcription factor that robustly induce HbF in erythroblasts. dWIZ-2 shows improved pharmacokinetic (PK) properties than dWIZ-1.

12T-O14 is a amidine-incorporated degradable (AID) lipid for versatile mRNA delivery. 12T-O14-LNPs mediate efficient intramuscular delivery of mRNA vaccines and systemic delivery of mRNA therapeutics without noticeable toxicity. 12T-O14 serves as a superior supplementary lipid to redirect liver-tropic LNPs to selectively target the lung or spleen via simple adjustment of the formulation.

REM0046127 (REM127) is a ReS19-T compound and restores calcium homeostasis and neutralizes tau- and Aβ-driven neurotoxicity. REM127 reduces toxicity and [Ca2+]cyto with EC50 of 15 and 19 nM, respectively but has no effect on tau expression or ATRA-dependent gene transcription.

MK-1084 is an orally bioavailable and low-dose KRAS/G12C covalent inhibitor with IC50 of 1.2 nM (GNE) and 9 nM (p-ERK), respectively.

KM822 is avselective, noncompetitive modulator of human dopamine transporter (DAT) with IC50 3.7 μM, which shows 30 and 50 folds higher than for human norepinephrine transporter (hNET) and human serotonin transporter (SERT), respectively.

CNDR-51997 is a brain-penetrant microtubule alterations-stabilizing small molecule and reduces both Aβ plaque and tau inclusion pathology in established mouse models of Alzheimer's disease.

OPB-171775 is a non-TKI compound that exhibits significant anticancer activity against gastrointestinal stromal tumor (GIST) regardless of KIT mutation status. OPB-171775 induces targeted cell death by inducing a complex between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12).

NF764 is an analogue of EN83 (CTNNB1 degrader) with improved potency with DC50 of 3.5 nM. NF764 only adducts C619 and shows much more selective than EN83 with 61 significant off-targets.

EN83 is a monovalent degrader of CTNNB1 that directly and covalently targets CTNNB1 three cysteines C466, C520, and C619, leading to destabilization and degradation of CTNNB1.

DHSEH is a sulfonium lipid for lung-specific mRNA delivery.

DOSEH is a sulfonium lipid for lung-specific mRNA delivery.

Bivamelagon is a melanocortin receptor agonist.

Turbinaric acid is a moderately cytotoxic secosqualene carboxylic acid that is isolated from the brown alga Turbinaria ornata.

IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research.

T-10418 is a potent and selective G2A agonist with EC50 of 0.82 μM. T-10418 exhibits higher potency than the reference and natural ligand 9-HODE and high selectivity among G protein-coupled receptors. T-10418 is a suitable candidate for in vivo studies on therapeutic potential of G2A agonism.

TG6A is a biodegradable and ionizable glycerolipid for cmRNA delivery. TG6A-LNP exhibits above 9-fold and 41-fold higher EGFP protein expression in MSCs than DLin-MC3-DMA-LNP and ALC-0315-LNP, respectively.

AZ'9567 is a potent inhibitor of MAT2A with pIC50 of 8.2. in vitro with excellent preclinical pharmacokinetic properties. AZ'9567 shows robust antitumor response in the MTAP KO HCT116 model.

LL-K12-18 is a dual-site molecular glue for CDK12-DDB1 complex with EC50 of 0.37 nM. LL-K12-18 shows an 80-fold enhanced potency than SR-4835 in MDA-MB-231 cells and with a 307-fold boost potency (EC50 = 0.03 nM) in MDA-MB-468 cells, while the degradation efficiency (DC50 = 0.38 nM) increased 50-fold.

DS18 is a DDB1-CDK12 molecular glue with EC50 of 8.771 nM.

Lipid A1-D1-5 is an ionizable lipid-like substance used for RNA interference therapy in heat-stable ionizable lipid-like nanoparticles (iLAND) for the treatment of hyperlipidemia.

GlyRS-IN-1 is a glycyl-tRNA synthase (GlyRS) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria.

GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation.

AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor.

(+)-UH 232 is a partially selective agonist of the D3 receptor with an intrinsic activity of 0.2-0.4. (+)-UH 232 antagonized quinpirole-induced mitogenesis with a Ki value of 9.4 nM.

Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells.

BLU-222 is an investigational, oral, potent, and selective CDK2 inhibitor. BLU-222 has shown robust anti-tumor activity in preclinical models of CCNE-aberrant ovarian, breast and gastric cancer.

Gepotidacin, also known as GSK-2140944, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin is a novel antibacterial drug candidate. Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively.

TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation.

VVD-130037 is an oral covalent activator of KEAP/NRF2 degrader.

BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research.

Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

BI-9508 is a potent and selective, brain-penetrant GPR88 agonist with EC50 of 47 nM.

Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.

Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br is an ADC linker that can be used to synthesize ABBV-154, ABBV-927, ABBV-368 or their analogs.

Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.

Mal-amido-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Val-Ala-PAB is a cleavable ADC linker that can be used for ADCs synthesis.

Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit.

Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation.

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.

Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.

Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis.

Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis.

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).

Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493).

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.

IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines.

Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.

Dinotefuran UF is the deuterium labeled γ-Tocotrienol. γ-Tocotrienol is an active form of vitamin E

ICA-1S is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι), does not inhibit PKC-ζ, the closely related atypical PKC family member.

Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

Acid-degradable Anionic Lipid (ADA) composed of anionic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

LI-3948 is a blood-brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor with IC50 of 16 nM and brain/plasma ratio of 1.3, respectively.

Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

Lipid CP-LC-1254 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

CP-LC-0729 is an ionizable lipid that significantly surpasses the MC3 in protein expression while showing no in vivo toxicity. CP-LC-0729 demonstrates a very high selectivity to lungs with a remarkable 32-fold increase in protein expression compared to MC3.

Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

Lipid CP-LC-0867 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

C9-200 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing C9-200 and encapsulating mRNA encoding erythropoietin (EPO) increase serum EPO levels in mice. LNPs containing C9-200 and encapsulating mRNA encoding the Cas9 nuclease and small-guide RNA (sgRNA) targeting transthyretin (TTR) induce 3-fold higher hepatic insertion and deletion (indel) formation than LNPs containing C12-200 (Item No. 36699) and encapsulating mRNA encoding Cas9 in mice.

Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer.

YHS-12 is an ionizable cationic lipid (pKa = 6.506) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.1 LNPs containing YHS-12 and the macrophage targeting peptide CRVLRSGSC and encapsulating mRNA encoding chimeric antigen receptor targeting methicillin-resistant S. aureus (MRSA) and siRNA targeting caspase-11 increase the phagocytosis rate of MRSA in RAW 264.7 macrophages and primary mouse bone marrow-derived macrophages (BMDMs). Intravenous administration of these LNPs decreases blood bacterial burden and increases survival in a model of sepsis using cyclophosphamide-induced immunosuppressed mice.

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.

Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis.

Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis.

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy.

Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)).

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors.

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD).

Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies.